Mesoblast is aiming to get 2012 approval for bone marrow treatment

05/12/2010 | Bloomberg Businessweek

Mesoblast, an Australian company that develops stem cell treatments, has agreed to acquire the remaining shares of Angioblast Systems that it doesn't yet own. The acquisition will give Mesoblast exclusive rights to various treatments, including a stem cell treatment that expands umbilical cord blood used in bone marrow transplants among leukemia patients. Mesoblast hopes to get the treatment approved by 2012.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA